AIM ImmunoTech News and Activities

AIM ImmunoTech is a company listed under the stock ticker AIM (US).

View the org chart displaying its 7 main executives

Most searched biographies at AIM ImmunoTech

• Thomas Equels, Executive Vice Chairman, Chief Executive Officer an...
• William Mitchell, Chairman of the Board
• Nancy Bryan, Director

Create your alert
to follow the executive moves at AIM ImmunoTech.

AIM ImmunoTech has 2,422 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• BridgeBio has just announced a $1,000 Million fundraising (posted on July 2 2026).
• Flare Therapeutics has just announced a $85 Million fundraising (posted on July 2 2026).
• Ipsen has announced the acquisition of Memo Therapeutics  (posted on July 1 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by AIM ImmunoTech

• Press Releases | AIM Immunotech
• AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
• AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
• AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
• AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
• AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
• View more press releases Close

Social media about AIM ImmunoTech

• AIM ImmunoTech on Wikipedia, Google News & Yahoo Finance
• AIM ImmunoTech on LinkedIn, X (Twitter) & YouTube